Protagen | GenomeWeb

Protagen

The license allows Inova to include the BICD2 biomarker in its portfolio of connective tissue disease reagents aimed at the diagnosis of systemic sclerosis.

The company now offers three CE-marked autoantibody assays — for BICD2, Scl70, and CENP-B — that can be used for clinical management of the condition.

According to the company, some of the autoantibodies it has identified as disease markers appear to be directed against potentially interesting drug targets.

Researchers from Protagen, Targos, and elsewhere have identified autoantibody biomarkers specific to patients diagnosed with prostate cancer.

The company hopes to identify a subset of predictive markers from a current panel of 100 proteins it identified as possibly useful through previous RA studies.

The companies are co-developing an assay that differentiates previously infected, seropositive Lyme disease patients from newly infected individuals.

The certification covers the development, production, and distribution of in vitro diagnostics for autoimmune disease.

The company said that it plans to use the funds to complete and commercialize in vitro diagnostic tests for rheumatoid arthritis, systemic lupus, and systemic sclerosis.

Protagen has agreed to provide Qiagen with access to proteomic technology for developing companion diagnostics for autoimmune disorders.

Pages

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.